A critical interaction between dopamine D2 receptors and endocannabinoids mediates the effects of cocaine on striatal GABAergic transmission

Neuropsychopharmacology

Volumn 29, Issue 8, 2004, Pages 1488-1497

  Centonze, Diego ^a   Battista, Natalia ^a   Rossi, Silvia ^a   Mercuri, Nicola B ^a   Finazzi Agrò, Alessandro ^a   Bernardi, Giorgio ^a   Calabresi, Paolo ^a   Maccarrone, Mauro ^a,b,c  

^a UNIVERSITY OF ROME TOR VERGATA   (Italy)

^b UNIVERSITY OF TERAMO   (Italy)

^c Mondino Tor Vergata Santa Lucia   (Italy)

Author keywords

Addiction; Anandamide; CBI receptors; GABA transmission; IPSC; Psychostimulants

Indexed keywords

2,3,4,5 TETRAHYDRO 7,8 DIHYDROXY 1 PHENYL 1H 3 BENZAZEPINE; 4 (1,1 DIMETHYLHEPTYL) 1',2',3',4',5',6' HEXAHYDRO 2,3' DIHYDROXY 6' (3 HYDROXYPROPYL)BIPHENYL; ANANDAMIDE; CANNABINOID DERIVATIVE; COCAINE; DOPAMINE 2 RECEPTOR; DOPAMINE 2 RECEPTOR STIMULATING AGENT; FATTY ACID AMIDASE; PHOSPHOLIPASE D; QUINPIROLE; RIMONABANT;

ANIMAL TISSUE; ARTICLE; BRAIN REGION; CHEMICAL INTERACTION; CONCENTRATION (PARAMETERS); CORPUS STRIATUM; DRUG ABUSE; DRUG DEPENDENCE; GABAERGIC TRANSMISSION; MALE; NONHUMAN; PRIORITY JOURNAL; RAT; STIMULATION;

2,3,4,5-TETRAHYDRO-7,8-DIHYDROXY-1-PHENYL-1H-3-BENZAZEPINE; AMIDOHYDROLASES; ANIMALS; ARACHIDONIC ACIDS; CEREBRAL CORTEX; COCAINE; CYCLOHEXANOLS; DOPAMINE AGONISTS; DOSE-RESPONSE RELATIONSHIP, DRUG; ELECTROPHYSIOLOGY; EXCITATORY POSTSYNAPTIC POTENTIALS; GAMMA-AMINOBUTYRIC ACID; MALE; NEOSTRIATUM; PATCH-CLAMP TECHNIQUES; POLYUNSATURATED ALKAMIDES; QUINPIROLE; RATS; RATS, WISTAR; RECEPTOR, CANNABINOID, CB1; RECEPTORS, DOPAMINE D2; SYNAPTIC TRANSMISSION; SYNAPTOSOMES; TETRAHYDROCANNABINOL;

EID: 3242763755     PISSN: 0893133X     EISSN: None     Source Type: Journal    
DOI: 10.1038/sj.npp.1300458     Document Type: Article

References (79)

1. Alonso R, Voutsinos B, Fournier M, Labie C, Steinberg R, Soulhac J et al (1999). Blockade of cannabinoid receptors by SR141716 selectively increases fos expression in rat mesocorticolimbic areas via reduced dopamine D2 function. Neuroscience 91: 607-620.
2. Amalric M, Koob GF (1993). Functionally selective neurochemical afferents and efferents of the mesocorticolimbic and nigrostriatal dopamine system. Prog Brain Res 99: 209-226.
3. Barker EL, Blakely RD (1995). Norepinephrine and serotonin transporters. Molecular targets of antidepressant drugs. In: Bloom FS, Kupfer DJ (eds). Psychopharmacology: The Fourth Generation of Progress. Raven Press Ltd: New York, pp 321-333.
4. Beltramo M, de Fonseca FR, Navarro M, Calignano A, Gorriti MA, Grammatikopoulos G et al (2000). Reversal of dopamine D(2) receptor responses by an anandamide transport inhibitor. J Neurosci 20: 3401-3407.
5. + cells. Biochem J 346: 369-374.
6. Berke JD, Hyman SE (2000). Addiction, dopamine, and the molecular mechanisms of memory. Neuron 25: 515-532.
7. Breivogel CS, Griffin G, Di Marzo V, Martin BR (2001). Evidence for a new G protein-coupled cannabinoid receptor in mouse brain. Mol Pharmacol 60: 155-163.
8. Cadas H, di Tomaso E, Piomelli D (1997). Occurrence and biosynthesis of endogenous cannabinoid precursors, N-arachidonoyl phosphatidylethanolamine, in rat brain. J Neurosci 17: 1226-1242.
9. Calabresi P, Centonze D, Bernardi G (2000). Electrophysiology of dopamine in normal and denervated striatal neurons. Trends Neurosci 23(Suppl 10): S57-63.
10. Calabresi P, De Murtas M, Bernardi G (1997). The neostriatum beyond the motor function: experimental and clinical evidence. Neuroscience 78: 39-60.
11. Canales JJ, Graybiel AM (2000). A measure of striatal function predicts motor stereotypy. Nat Neurosci 3: 377-383.
12. Carlson G, Wang Y, Alger BE (2002). Endocannabinoids facilitate the induction of LTP in the hippocampus. Nat Neurosci 5: 723-724.
13. Carlsson A, Waters N, Holm-Waters S, Tedroff J, Nilsson M, Carlsson ML (2001). Interactions between monoamines, glutamate and GABA in schizophrenia: new evidence. Ann Rev Pharmacol Toxicol 41: 237-260.
14. Centonze D, Grande C, Usiello A, Gubellini P, Erbs E, Martin AB et al (2003). Receptor subtypes involved in the presynaptic and postsynaptic actions of dopamine on striatal interneurons. J Neurosci 23: 6245-6254.
15. Centonze D, Picconi B, Baunez C, Borrelli E, Pisani A, Bernardi G et al (2002). Cocaine and amphetamine depress striatal GABAergic synaptic transmission through D2 dopamine receptors. Neuropsychopharmacology 26: 164-175.
16. Centonze D, Picconi B, Gubellini P, Bernardi G, Calabresi P (2001). Dopaminergic control of synaptic plasticity in the dorsal striatum. Eur J Neurosci 13: 1071-1077.
17. Chaperon F, Soubrie P, Puech AJ, Thiebot MH (1998). Involvement of central cannabinoid (CB1) receptors in the establishment of place conditioning in rats. Psychopharmacology 135: 324-332.
18. Coutts AA, Anavi-Goffer S, Ross RA, MacEwan DJ, Mackie K, Pertwee RG et al (2001). Agonist-induced internalization and trafficking of cannabinoid CB1 receptors in hippocampal neurons. J Neurosci 21: 2425-2433.
19. Delgado A, Sierra A, Querejeta E, Valdiosera RF, Aceves J (2000). Inhibitory control of the GABAergic transmission in the rat neostriatum by D2 dopamine receptors. Neuroscience 95: 1043-1048.
20. De Vries TJ, Shaham Y, Homberg JR, Crombag H, Schuurman K, Dieben J et al (2001). A cannabinoid mechanism in relapse to cocaine seeking. Nat Med 7: 1151-1154.
21. Di Marzo V, Fontana A, Cadas H, Schinelli S, Cimino G, Schwartz JC et al (1994). Formation and inactivation of endogenous cannabinoid anandamide in central neurons. Nature 372: 686-691.
22. Di Marzo V, Hill MP, Bisogno T, Crossman AR, Brotchie JM (2000). Enhanced levels of endogenous cannabinoids in the globus pallidus are associated with a reduction in movement in an animal model of Parkinson's disease. FASEB J 14: 1432-1438.
23. Emrich HM, Leweke FM, Schneider U (1997). Towards a cannabinoid hypothesis of schizophrenia: cognitive impairments due to dysregulation of the endogenous cannabinoid system. Pharmacol Biochem Behav 56: 803-807.
24. Everitt BJ, Wolf ME (2002). Psychomotor stimulant addiction: a neural systems perspective. J Neurosci 22: 3312-3320.
25. Gerdeman GL, Partridge JG, Lupica CR, Lovinger DM (2003). It could be habit forming: drugs of abuse and striatal synaptic plasticity. Trends Neurosci 26: 184-192.
26. Gerdeman GL, Ronesi J, Lovinger DM (2002). Postsynaptic endocannabinoid release is critical to long-term depression in the striatum. Nat Neurosci 5: 446-451.
27. Giuffrida A, Parsons LH, Kerr TM, Rodriguez de Fonseca F, Navarro M, Piomelli D (1999). Dopamine activation of endogenous cannabinoid signaling in dorsal striatum. Nat Neurosci 2: 358-363.
28. Gorriti MA, Rodriguez de Fonseca F, Navarro M, Palomo T (1999). Chronic (-)-delta-9-tetrahydrocannabinol treatment induces sensitization to the psychomotor effects of amphetamine in rats. Eur J Pharmacol 365: 133-142.
29. Graybiel AM, Moratalla R, Robertson HA (1990). Amphetamine and cocaine induce drug-specific activation of the c-fos gene in striosome-matrix compartments and limbic subdivisions of the striatum. Proc Natl Acad Sci USA 87: 6912-6916.
30. Gubellini P, Picconi B, Bari M, Battista N, Calabresi P, Centonze D et al (2002). Experimental parkinsonism alters endocannabinoid degradation: implications for striatal glutamatergic transmission. J Neurosci 22: 6900-6907.
31. Hermann H, Marsicano G, Lutz B (2002). Coexpression of the cannabinoid receptor type 1 with dopamine and serotonin receptors in distinct neuronal subpopulations of the adult mouse forebrain. Neuroscience 109: 451-460.
32. Hohmann AG, Herkenham M (2000). Localization of cannabinoid CB1 receptor mRNA in neuronal subpopulations of rat striatum: a double-label in situ hybridization study. Synapse 37: 71-80.
33. Hsieh C, Brown S, Derleth C, Mackie K (1999). Internalization and recycling of the CB1 cannabinoid receptor. J Neurochem 73: 493-501.
34. Huang YC, Wang SJ, Chiou LC, Gean PW (2003). Mediation of amphetamine-induced long-term depression of synaptic transmission by CB1 cannabinoid receptors in the rat amygdala. J Neurosci 23: 10311-10320.
35. Hyman SE, Malenka RC (2001). Addiction and the brain: the neurobiology of compulsion and its persistence. Nat Rev Neurosci 2: 695-703.
36. Iversen L (2003). Cannabis and the brain. Brain 126: 1252-1270.
37. Jog MS, Kubota Y, Connolly CI, Hillegaart V, Graybiel AM (1999). Building neural representations of habit. Science 286: 1745-1749.
38. Johanson C-E, Schuster CR (1995). Cocaine. In: Bloom FE, Kupfer DJ (eds). Psychopharmacology: The Fourth Generation of Progress. Raven Press Ltd: New York. pp 1685-1697.
39. Kelly PH, Seviour PW, Iversen SD (1975). Amphetamine and apomorphine responses in the rat following 6-OHDA lesions of the nucleus accumbens septi and corpus striatum. Brain Res 94: 507-522.
40. Kita H (1996). Glutamatergic and GABAergic postsynaptic responses of striatal spiny neurons to intrastriatal and cortical stimulation recorded in slice preparations. Neuroscience 70: 925-940.
41. Kiyatkin EA, Rebec GV (2000). Dopamine-independent action of cocaine on striatal and accumbal neurons. Eur J Neurosci 12: 1789-1800.
42. Koos T, Tepper JM (1999). Inhibitory control of neostriatal projection neurons by GABAergic interneurons. Nat Neurosci 2: 467-472.
43. Leckman JF, Riddle MA (2000). Tourette's syndrome: when habit-forming systems form habits of their own? Neuron 28: 349-354.
44. Ledent C, Valverde O, Cossu G, Petitet F, Aubert JF, Beslot F et al (1999). Unresponsiveness to cannabinoids and reduced addictive effects of opiates in CB1 receptor knockout mice. Science 283: 401-404.
45. Maccarrone M, Attinà M, Bari M, Cartoni A, Ledent C, Fínazzí-Agrò A (2001). Anandamide degradation and N-acylethanolamines level in wild-type and CB1 cannabinoid receptor knockout mice of different ages. J Neurochem 78: 339-348.
46. Maccarrone M, Bari M, Di Rienzo M, Finazzi-Agrò A, Rossi A (2003b). Progesterone activates fatty acid amide hydrolase (FAAH) promoter in human T lymphocytes through the transcription factor Ikaros. Evidence for a synergistic effect of leptin. J Biol Chem 278: 32726-32732.
47. Maccarrone M, Di Rienzo M, Battista N, Gasperi V, Guerrieri P, Rossi A et al (2003c). The endocannabinoid system in human keratinocytes. Evidence that anandamide inhibits epidermal differentiation through CB1 receptor-dependent inhibition of protein kinase C, activating protein-1 and transglutaminase. J Biol Chem 278: 33896-33903.
48. Maccarrone M, Fezza F, Finazzi-Agrò A (2004). Levels of N-acylethanolamines in human tumors: in search of reliable data. Lipids 39, (in press).
49. Maccarrone M, Gubellini P, Bari M, Picconi B, Battista N, Centonze D et al (2003a). Levodopa treatment reverses endocannabinoid system abnormalities in experimental parkinsonism. J Neurochem 85: 1018-1025.
50. Maldonado R, Rodriguez de Fonseca F (2002). Cannabinoid addiction: behavioral models and neural correlates. J Neurosci 22: 3326-3331.
51. Mansour A, Watson SJ (1995). Dopamine receptor expression in the central nervous system. In: Bloom FE, Kupfer DJ (eds). Psychopharmacology: The Fourth Generation of Progress. Raven Press Ltd: New York. pp 207-219.
52. Martin M, Ledent C, Parmentier M, Maldonado R, Valverde O (2000). Cocaine, but not morphine, induces conditioned place preference and sensitization to locomotor responses in CB1 knockout mice. Eur J Neurosci 12: 4038-4046.
53. Meschler JP, Conley TJ, Howlett AC (2000). Cannabinoid and dopamine interaction in rodent brain: effects on locomotor activity. Pharmacol Biochem Behav 67: 567-573.
54. 31P NMR and enzyme activity study. J Lipid Res 41: 985-990.
55. Moratalla R, Vickers EA, Robertson HA, Cochran BH, Graybiel AM (1993). Coordinate expression of c-fos and junB is induced in the rat striatum by cocaine. J Neurosci 13: 423-433.
56. Nava F, Carta G, Battasi AM, Gessa GL (2000). D(2) dopamine receptors enable delta(9)-tetrahydrocannabinol induced memory impairment and reduction of hippocampal extracellular acetylcholine concentration. Br J Pharmacol 130: 1201-1210.
57. Navarro M, Chowen JA, Carrera MR, Del Arco I, Villanua MA, Martin Y et al (1998). CB1 cannabinoid receptor antagonist-induced opiate withdrawal in morphine-dependent rats. Neuroreport 9: 3397-3402.
58. Nisenbaum ES, Berger TW (1992). Functionally distinct subpopulations of striatal neurons are differentially regulated by GABAergic and dopaminergic inputs. I. In vivo analysis. Neuroscience 48: 561-578.
59. Obeso JA, Rodríguez-Oroz MC, Rodríguez M, Lanciego JL, Artieda J, Gonzalo N et al (2000). Pathophysiology of the basal ganglia in Parkinson's disease. Trends Neurosci 23(10 Suppl): S8-S19.
60. Okamoto Y, Morishita J, Tsuboi K, Tonai T, Ueda N (2004). Molecular characterization of a phospholipase D generating anandamide and its congeners. J Biol Chem 279: 5298-5305.
61. Packard MG, Knowlton BJ (2002). Learning and memory functions of the basal ganglia. Annu Rev Neurosci 25: 563-593.
62. Patel S, Rademacher DJ, Hillard CJ (2003). Differential regulation of the endocannabinoids anandamide and 2-arachidonylglycerol within the limbic forebrain by dopamine receptor activity. J Pharmacol Exp Ther 306: 880-888.
63. Pertwee RG (1997). Pharmacology of cannabinoid CB1 and CB2 receptors. Pharmacol Ther 74: 129-180.
64. Pertwee RG, Ross RA (2002). Cannabinoid receptors and their ligands. Prostag Leukotr Essential Fatty Acids 66: 101-121.
65. Picconi B, Centonze D, Hakansson K, Bernardi G, Greengard P, Fisone G et al (2003). Loss of bidirectional striatal synaptic plasticity in L-DOPA-induced dyskinesia. Nat Neurosci 6: 501-506.
66. Piomelli D (2003). The molecular logic of endocannabinoid signalling. Nat Rev Neurosci 4: 873-884.
67. Pisani A, Bonsi P, Centonze D, Martorana A, Fusco F, Sancesario G et al (2003). Activation of beta1-adrenoceptors excites striatal cholinergic interneurons through a cAMP-dependent, protein kinase-independent pathway. J Neurosci 23: 5272-5282.
68. Plenz D, Kitai ST (1998). Up and down states in striatal medium spiny neurons simultaneously recorded with spontaneous activity in fast-spiking interneurons studied in cortex-striatum-substantia nigra organotypic cultures. J Neurosci 18: 266-283.
69. Pontieri FE, Monnazzi P, Scontrini A, Buttarelli FR, Patacchioli FR (2001). Behavioral sensitization to heroin by cannabinoid pretreatment in the rat. Eur J Pharmacol 421: R1-R3.
70. Schmid PC, Paria BC, Krebsbach RJ, Schmid HHO, Dey SK (1997). Changes in anandamide levels in mouse uterus are associated with uterine receptivity for embryo implantation. Proc Natl Acad Sci USA 94: 4188-4192.
71. Stoof JC, Kebabian JW (1981). Opposing roles for D-1 an D-2 dopamine receptors in efflux of cyclic AMP from rat neostriatum. Nature 294: 366-368.
72. Surmeier DJ, Song W-J, Yan Z (1996). Coordinated expression of dopamine receptors in neostriatal medium spiny neurons. J Neurosci 16: 6579-6591.
73. Szabo B, Dorner L, Pfreundtner C, Norenberg W, Starke K (1998). Inhibition of GABAergic inhibitory postsynaptic currents by cannabinoids in rat corpus striatum. Neuroscience 85: 395-403.
74. Tanda G, Munzar P, Goldberg SR (2000). Self-administration behavior is maintained by the psychoactive ingredient of marijuana in squirrel monkeys. Nat Neurosci 3: 1073-1074.
75. Tunstall MJ, Oorschot DE, Kean A, Wickens JR (2002). Inhibitory interactions between spiny projection neurons in the rat striatum. J Neurophysiol 88: 1263-1269.
76. Valjent E, Pages C, Rogard M, Besson MJ, Maldonado R, Caboche J (2001). Delta 9-tetrahydrocannabinol-induced MAPK/ERK and Elk-1 activation in vivo depends on dopaminergic transmission. Eur J Neurosci 14: 342-352.
77. Vallone D, Picetti P, Borrelli E (2000). Structure and function of dopamine receptors. Neurosci Biobehav Rev 24: 125-132.
78. Wilms K, Vierig G, Davidowa H (2001). Interactive effects of cholecystokinin-8S and various serotonin receptor agonists on the firing activity of neostriatal neurones in rats. Neuropeptides 35: 257-270.
79. Yang H-YT, Karoum F, Felder C, Badger H, Wang T-CL, Markey SP (1999). GC/MS analysis of anandamide and quantification of N-arachidonoyl- phosphatidylethanolamides in various brain regions, spinal cord, testis, and spleen of the rat. J Neurochem 72: 1959-1968.